KPF
ABUS icon

K2 Principal Fund’s Arbutus Biopharma ABUS Stock Holding History

K2 Principal Fund’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,000
Closed -$175K – 174
2015
Q1 		$175K Buy
+10,000
New +$205K 0.04% 139

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

K2 Principal Fund's ABUS Position: Q4 2018 in Review

K2 Principal Fund sold out of Arbutus Biopharma (ABUS) in Q4 2018, closing a stake of 11,884 shares — an estimated $112K sold.

K2 Principal Fund first reported a position in ABUS in Q4 2014 and held it in 14 quarters. The position peaked at $1.55M in Q3 2017. 71 funds tracked by Wall St. Rank hold ABUS as of Q4 2018.

  • K2 Principal Fund reported no remaining Arbutus Biopharma position as of Q4 2018 after selling out during the quarter.
  • K2 Principal Fund sold 11,884 Arbutus Biopharma shares in Q4 2018, an estimated $112K.
  • K2 Principal Fund first reported a position in Arbutus Biopharma in Q4 2014 and held it in 14 quarters.
  • K2 Principal Fund's Arbutus Biopharma position peaked at $1.55M in Q3 2017.
  • 71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2018.

Based on K2 Principal Fund's 13F filing for Q4 2018, filed 13 Feb 2019.